Jenny Seligmann: Another Year, Another FOXTROT Platform Focus Meeting!
Jenny Seligmann/LinkedIn

Jenny Seligmann: Another Year, Another FOXTROT Platform Focus Meeting!

Jenny Seligmann, Professor of Gastrointestinal Oncology at University of Leeds, shared on LinkedIn:

“Another year another FOXTROT Platform focus meeting!”

The FOxTROT Programme

FOxTROT is an international clinical research programme focused on improving bowel cancer treatment.

It is sponsored by the University of Leeds and conducted by its Clinical Trials Research Unit (CTRU).

The programme investigates different treatment approaches for bowel cancer, particularly the use of chemotherapy before surgery.

“Lots to celebrate.

  • Over 850 pts recruited
  • FOXTROT 4 and 5 completed recruitment
  • FOXTROT 6 open next month
  • FOXTROT 7 contract signed
  • Translational data and CRC STARS data coming soon! Exciting collaboration with Natera

A long way to go however and maintaining momentum key!
Thanks to a fabulous team especially Nancy F. and our fabulous PPIE group.

Thanks to our funders Yorkshire Cancer Research and GSK, Pierre Fabre Oncology, Merck Group.”

FOxTROT 1

A trial looking at chemotherapy before surgery for bowel cancer

FOxTROT 1 was the first study to investigate the use of preoperative chemotherapy as part of the FOxTROT approach.

This international study was completed in 2019 and included 1,052 patients with Stage II or III bowel cancer from the UK, Sweden and Denmark.

Of these, 698 patients received six weeks of preoperative chemotherapy, followed by a further 6–18 weeks of postoperative chemotherapy, depending on their post-surgical assessment.

The remaining 354 patients received standard treatment, consisting of surgery followed by 24 weeks of chemotherapy. Both groups received the same chemotherapy agents.

Clinical outcomes were subsequently analysed and compared between the two groups.

The study found the following for the first group of 698 patients, compared with those receiving standard treatment:

  • Receiving the chemotherapy before surgery was safe for patients
  • Fewer serious complications arose following the surgery
  • For most patients the chemotherapy shrank their tumour making surgery less complex
  • The cancer came back in fewer patients – 5 fewer in every hundred patients taking part in the research when compared with patients receiving standard treatment (as measured after 2 years).
Title: Preoperative Chemotherapy for Operable Colon Cancer: Mature Results of an International Randomized Controlled Trial

Authors: Dion Morton, Matthew Seymour, Laura Magill, Kelly Handley, James Glasbey, Bengt Glimelius, Andy Palmer, Jenny Seligmann, Søren Laurberg, Keigo Murakami, Nick West, Philip Quirke, Richard Gray

Read the article

 

FOxTROT 2

Is earlier Chemotherapy treatment better for bowel cancer patients over 70 and for those with other medical conditions?

Bowel cancer is more common in older people, with an average age at diagnosis of 71.

Due to the effects of surgery and other existing health conditions, some patients may not be fit enough to receive chemotherapy after surgery.

In FOxTROT 2, patients are randomly assigned to one of two groups: the FOxTROT 2 treatment approach or standard treatment.

The study aims to determine whether older patients with bowel cancer, or those with other significant health conditions, can also benefit from neoadjuvant chemotherapy, compared with the standard approach of surgery first.

Both groups receive the same combination of chemotherapy drugs. In the FOxTROT 2 approach, these drugs are given for six weeks before surgery.

The theory for this trial is based on the results of FOxTROT 1.

The results of this trial can be found here: A trial looking at chemotherapy before surgery for bowel cancer (FOxTROT).

 

FOxTROT 3

Is three drug Chemotherapy before and after surgery better overall than two drug Chemotherapy for bowel cancer patients?

The conventional treatment approach for bowel cancer involves surgical removal of the tumour, typically followed by adjuvant chemotherapy.

However, the FOxTROT 1 study demonstrated that preoperative chemotherapy was safe and lowered the risk of cancer recurrence.

As a result, preoperative chemotherapy is now a standard treatment option for some patients with bowel cancer.

 

FOxTROT 4

Bowel cancer patients with a ‘BRAFv600E’ genetic mutation: Are ‘targeted drugs’ better than standard chemotherapy when given before surgery?

Around one in ten patients diagnosed with stage II or III bowel cancer have a specific genetic alteration known as a BRAF mutation.

FOxTROT 4 evaluates the safety and effectiveness of two neoadjuvant treatment approaches: standard chemotherapy and novel targeted therapies.

Targeted therapies are designed to act on specific genes or proteins that support cancer cell survival and growth.

These targeted treatments have been shown to be effective in patients with the BRAF V600E mutation and stage IV bowel cancer.

FOxTROT 5

A phase II trial evaluating perioperative dostarlimab in older and/or frail patients with locally advanced but operable deficient mismatch repair colon cancer

The aim of FOxTROT 5 is to identify an improved treatment for patients with bowel cancer whose cancer cells have an abnormality known as Deficient Mismatch Repair (dMMR).

Standard chemotherapy may be less effective in these patients.

The study evaluates dostarlimab in patients with dMMR bowel cancer. Its efficacy has already been demonstrated in other dMMR malignancies.